Empirical Financial Services LLC d.b.a. Empirical Wealth Management Grows Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Empirical Financial Services LLC d.b.a. Empirical Wealth Management increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 22.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,547 shares of the biopharmaceutical company’s stock after purchasing an additional 474 shares during the period. Empirical Financial Services LLC d.b.a. Empirical Wealth Management’s holdings in Regeneron Pharmaceuticals were worth $1,814,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the company. Rakuten Securities Inc. boosted its position in Regeneron Pharmaceuticals by 380.0% in the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 19 shares during the period. FSA Wealth Management LLC purchased a new stake in Regeneron Pharmaceuticals in the 3rd quarter valued at about $26,000. Fairfield Financial Advisors LTD purchased a new stake in Regeneron Pharmaceuticals in the 3rd quarter valued at about $37,000. Truvestments Capital LLC purchased a new stake in Regeneron Pharmaceuticals in the 3rd quarter valued at about $39,000. Finally, Valley Wealth Managers Inc. purchased a new stake in Regeneron Pharmaceuticals in the 3rd quarter valued at about $49,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. Oppenheimer lowered their price objective on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating for the company in a research report on Wednesday, November 6th. Royal Bank of Canada reduced their price target on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating for the company in a report on Friday, November 1st. UBS Group lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price target for the company from $1,130.00 to $738.00 in a report on Thursday, January 16th. Barclays reduced their price target on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating for the company in a report on Friday, November 1st. Finally, Truist Financial reduced their price target on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a report on Wednesday, January 8th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $1,006.71.

Regeneron Pharmaceuticals Stock Performance

REGN opened at $684.71 on Tuesday. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The company has a market cap of $75.24 billion, a price-to-earnings ratio of 16.94, a PEG ratio of 1.59 and a beta of 0.10. Regeneron Pharmaceuticals, Inc. has a 52-week low of $666.25 and a 52-week high of $1,211.20. The firm’s fifty day simple moving average is $727.19 and its two-hundred day simple moving average is $936.01.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.